Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Leases (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Leases for 4 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed N/A to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.1 million for FY2025, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $2.1 million at Phathom Pharmaceuticals, down from $2.1 million in the prior quarter.
  • The five-year high for Operating Leases was $2.1 million in Q3 2025, with the low at $133000.0 in Q2 2024.
  • Average Operating Leases over 4 years is $988153.8, with a median of $945000.0 recorded in 2023.
  • The sharpest move saw Operating Leases plummeted 83.14% in 2024, then surged 342.86% in 2025.
  • Over 4 years, Operating Leases stood at $1.1 million in 2022, then tumbled by 57.92% to $462000.0 in 2023, then tumbled by 71.21% to $133000.0 in 2024, then surged by 1452.63% to $2.1 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $2.1 million, $2.1 million, and $589000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.